SCHEDULE: Blue Owl Capital Discloses 5.92% Stake in Biomea Fusion

Blue Owl Capital Holdings LP has reported a 5.92% beneficial ownership stake in Biomea Fusion, Inc., primarily through warrants.

Summary

• Blue Owl Capital Holdings LP reported beneficial ownership of 4,451,219 shares of Biomea Fusion, Inc. common stock.
• This represents 5.92% of Biomea Fusion, Inc.'s outstanding common stock.
• The reported shares are issuable upon the exercise of warrants, with each warrant acquiring one share of Common Stock.
• The percentage of class is calculated based on 70,703,639 shares of Common Stock outstanding as of October 31, 2025, as reported in Biomea Fusion's 10-Q, plus the 4,451,219 shares issuable from warrants.
• Blue Owl Capital Holdings LP holds shared voting power and shared dispositive power over all 4,451,219 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Biomea Fusion, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of a significant passive investment. The presence of a major institutional investor like Blue Owl Capital Holdings LP, even in a passive role, can be seen as a modest positive signal for Biomea Fusion.

Positives

• The disclosure of a significant 5.92% stake by an institutional investor like Blue Owl Capital Holdings LP can be interpreted as a positive signal of confidence in Biomea Fusion, Inc.'s long-term prospects.

Future Outlook

No specific future outlook or guidance is provided in this beneficial ownership report.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a significant, passive investment by an institutional entity. For Biomea Fusion, a biotechnology company, the entry of Blue Owl Capital Holdings LP as a substantial shareholder could signal increased institutional confidence in its long-term potential, particularly given the investment is via warrants, suggesting a strategic entry point.

Comparison to Industry Standards

• This filing pertains to an ownership stake rather than operational or financial results, so direct comparison to industry performance benchmarks is not applicable.
• StockSavvy.ai observes that institutional ownership levels are a common metric for investor confidence. While specific comparable companies are not mentioned in the filing, similar biotech firms often see varying levels of institutional investment, with significant passive stakes like this generally viewed favorably by the market.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide a sense of stability and validation for existing shareholders.
• Company Management: Awareness of a significant passive investor may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing reports a passive beneficial ownership stake by an institutional investor, which is a routine disclosure and does not provide new information warranting a change in investment thesis. It confirms institutional interest but offers no new operational or financial data to justify a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Biomea Fusion, Blue Owl Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Pharmaceuticals